CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Caribou Biosciences Inc (CRBU) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock shows bullish technical indicators, positive analyst ratings with significant upside potential, and strong hedge fund interest. Despite short-term financial challenges, the company's revenue growth and promising pipeline in CAR-T therapies make it a compelling long-term investment.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 68.747, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 1.875, and resistance is at 2.255, suggesting a favorable entry point near current levels.
Hedge funds are significantly increasing their positions, with a 1731.04% increase in buying over the last quarter. Analysts have raised price targets to $13, citing promising CAR-T therapy pipeline and potential peak sales of nearly $1B for lead assets.
The company faces funding challenges for launching pivotal studies, and financial performance shows a net income decline and negative EPS growth.
In Q4 2025, revenue increased by 89.74% YoY to $3.94M, but net income dropped by 25.36% YoY to -$26.49M. EPS also declined by 28.21% YoY to -$0.28, while gross margin remained stable at 100%.
Analysts maintain a positive outlook with an Outperform rating and a price target of $13, indicating significant upside from the current price of $2.17. The company's CAR-T therapy pipeline is seen as a key growth driver, despite funding concerns.
